Making waves

Article

I would like to give a warm welcome to all of our readers and, particularly to those of you who have recently joined the many ophthalmologists across Europe who read our publication. I have been delighted by the response we have had to Ophthalmology Times Europe so far and I would like to thank you all for your very kind words of support and encouragement. We have tried to make Ophthalmology Times Europe a little different to other publications out there, not only in the world of ophthalmology, but across industries. By providing broad coverage of the industry and presenting arguments and ideas in an easily digestible format, it has been our mission to supply you with something that you enjoy reading.

So if you think we are missing something or if you would like to make your voice heard, please do get in touch. I am always happy to hear from you.

This month's feature, Wavefront technologies: what's best for your patient? embarks on a mission to help you find the wavefront treatment that will benefit your patient most. By profiling some of the technologies currently on the market, we have tried to give you a taste of what's out there and what impact, changing your approach to laser surgery, could have on your practice. Many studies have been published proving the benefits of wavefront treatment over conventional excimer laser surgery. However, the current argument is, of the wavefront technologies available, which one's best? There will always be issues relating to cost effectiveness and speed of treatment but take a look at the facts and make your judgement.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.